Sachdeva R, Prayaga S, Bansal D, Bagwe S, Hughes B, Molavi B, Romeo F, Mehta J L
Department of Internal Medicine, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System Little Rock, AR, USA.
Minerva Cardioangiol. 2009 Feb;57(1):57-75.
The exponential growth of percutaneous coronary intervention (PCI) has in large part been due to expansion of the indications to include the procedure in patients with extensive coronary disease, multiple risk factors, older age and comorbidities. Improvement in PCI equipment, development of new interventional techniques, and availability of myocardial and systemic support techniques have all contributed to this growth. With these advances, patients once considered high risk for PCI are no longer considered high risk. This article reviews the complex coronary lesions challenges, various interventional and pharmacologic strategies for optimal results and novel technology.
经皮冠状动脉介入治疗（PCI）的指数式增长在很大程度上归因于适应证的扩大，将该手术纳入患有广泛冠状动脉疾病、多种危险因素、老年及合并症的患者。PCI设备的改进、新介入技术的发展以及心肌和全身支持技术的可用性都促成了这种增长。随着这些进展，曾经被认为PCI高风险的患者不再被视为高风险。本文综述了复杂冠状动脉病变的挑战、实现最佳结果的各种介入和药物策略以及新技术。
